Immunic Inc

Immunic is a biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing these small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt; and IMU-856 targets the restoration of the intestinal barrier function. The company's development program, IMU-838, is in clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis.
  • TickerIMUX
  • ISINUS4525EP1011
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Wedbush Research

Wedbush Morning Call - Aug 10 2020 6:58AM

Andreas Argyrides ...
  • Liana Moussatos
  • Shveta Dighe

P2 EMPhASIZES IMU-838’s Best-in-Class Profile; Next, ACTRIMS, P2/COVID-19 in Q3

Andreas Argyrides ...
  • Liana Moussatos
  • Shveta Dighe

IMU-838+Tamiflu® Combo/COVID-19 Ph 2 Trial Initiated; Next, RRMS Data in August

Wedbush Research

Wedbush Morning Call - Jul 26 2020 6:53PM

Andreas Argyrides ...
  • Ashiq Mubarack
  • David Nierengarten
  • Jeffrey La Rosa
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Aug 10 2020 6:58AM

Andreas Argyrides ...
  • Liana Moussatos
  • Shveta Dighe

P2 EMPhASIZES IMU-838’s Best-in-Class Profile; Next, ACTRIMS, P2/COVID-19 in Q3

Andreas Argyrides ...
  • Liana Moussatos
  • Shveta Dighe

IMU-838+Tamiflu® Combo/COVID-19 Ph 2 Trial Initiated; Next, RRMS Data in August

Wedbush Research

Wedbush Morning Call - Jul 26 2020 6:53PM

Andreas Argyrides ...
  • Ashiq Mubarack
  • David Nierengarten
  • Jeffrey La Rosa
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

IMMUNIC INCO. sees a downgrade to Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of IMMUNIC INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date January 24, 2020, the closing price was USD 8.21 and its target price was estimated at USD 2.13.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch